Luminal B, Human Epidermal Growth Factor Receptor 2 (HER2/neu), and Triple-Negative Breast Cancers Associated With a Better Chemotherapy Response Than Luminal A Breast Cancers in Postneoadjuvant Settings.

Hashmi, Atif A; Bukhari, Ummara; Najam, Javeria; Dowlah, Tanim; Ali, Abrahim H; Diwan, Muhammad Asad; Anjali, Fnu; Sham, Sunder; Zia, Shamail; Irfan, Muhammad

Hashmi, Atif A; Bukhari, Ummara; Najam, Javeria; Dowlah, Tanim; Ali, Abrahim H; Diwan, Muhammad Asad; Anjali, Fnu; Sham, Sunder; Zia, Shamail; Irfan, Muhammad.

Afiliación

Hashmi AA; Pathology, Liaquat National Hospital and Medical College, Karachi, PAK.
Bukhari U; Internal Medicine, Jinnah Sindh Medical University, Karachi, PAK.
Najam J; Internal Medicine, Liaquat National Hospital and Medical College, Karachi, PAK.
Dowlah T; Internal Medicine, Bangladesh Medical College, Dhaka, BGD.
Ali AH; Internal Medicine, Bangladesh Medical College, Dhaka, BGD.
Diwan MA; Pathology, The Aga Khan University, Karachi, PAK.
Anjali F; Internal Medicine, Sakhi Baba General Hospital, Sukkur, PAK.
Sham S; Pathology, Lenox Hill Hospital, New York, USA.
Zia S; Pathology, Jinnah Sindh Medical University, Karachi, PAK.
Irfan M; Statistics, Liaquat National Hospital and Medical College, Karachi, PAK.

Cureus ; 15(6): e40066, 2023 Jun.

Article en En | MEDLINE | ID: mdl-37425505

Palabras clave

chemotherapy response; her2/neu; luminal a; luminal b; postneoadjuvant breast cancer

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Cureus Año: 2023 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google